DexCom Inc (DXCM) stock
DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 22/3031% below fair value
$82.04+0.43 (+0.53%)
Close on Nov 17, 2026Market cap $30.60BP/E 32.3Yield –
DexCom price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
DexCom's price to sales ratio was 6.1× on Nov 11, 2026, against 5.5× a year earlier. Over the last 5 years it ranged from 4.9× to 22.4×, with a median of 11.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 6.1× | +0.4 |
| 2025 | Dec 31, 2025 | 5.7× | −2.0 |
| 2024 | Dec 31, 2024 | 7.7× | −6.4 |
| 2023 | Dec 29, 2023 | 14.1× | −1.6 |
| 2022 | Dec 30, 2022 | 15.7× | −6.8 |
| 2021 | Dec 31, 2021 | 22.4× | +2.9 |
| 2020 | Dec 31, 2020 | 19.5× | +4.7 |
| 2019 | Dec 31, 2019 | 14.8× | +3.2 |
| 2018 | Dec 31, 2018 | 11.6× | +4.2 |
| 2017 | Dec 29, 2017 | 7.5× | −2.0 |
| 2016 | Dec 30, 2016 | 9.5× | −9.3 |
| 2015 | Dec 31, 2015 | 18.7× | +0.2 |
| 2014 | Dec 31, 2014 | 18.6× | +0.6 |
| 2013 | Dec 31, 2013 | 17.9× | +7.4 |
| 2012 | Dec 31, 2012 | 10.6× | +1.5 |
| 2011 | Dec 30, 2011 | 9.0× | – |
See a number that looks wrong?